OralParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Progesterone

CAS 57-83-0

Progesterone (CAS 57-83-0) is a Phase 4 pharmaceutical compound with 21 bioactivity targets and 4,968 adverse event associations.

SOURCE NLM DailyMed
Label records
1
SOURCE EMBL-EBI ChEMBL
Bioactivity
36
SOURCE DrugCentral / FAERS
Adverse signals
4,968
SOURCE IUPHAR / PharmGKB
PubMed IDs
9
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Progesterone
CAS Number
57-83-0
UNII
4G7DS2Q64Y
InChIKey
RJKFOVLPORLFTN-LEKSSAKUSA-N
ChEMBL ID
CHEMBL103
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
CrinonePrometrium
black box warningdosed ingredientnatural productoralparenteraltherapeutic flagtopical
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL103 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DailyMed SPL XML 1 label row

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Natural Progesterone PROGESTERONE
4G7DS2Q64Y
 PROGESTERONE 20260505
SOURCE ChEMBL 36 activities + assays 36 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 29459.69740932642 nM 117 -
- AC50 19467.198958333334 nM 96 -
- IC50 10349.739027777778 nM 70 -
- GI50 19713.088833333335 nM 60 -
- Ki 4738.158613636363 nM 44 -
- EC50 4462.061612903226 nM 31 -
- Kd 159.822 nM 5 -
- IC50 50 ug.mL-1 1 -
Sodium/nucleoside cotransporter 1
Transporter
 Ki 5.174 - Homo sapiens
Sigma non-opioid intracellular receptor 1
Membrane receptor
 Ki 6.59 - Homo sapiens
Multidrug resistance protein 1
Transporter
 IC50 4.32 - Homo sapiens
Glucocorticoid receptor
Nuclear hormone receptor
 Ki 7.52 - Homo sapiens
Mineralocorticoid receptor
Nuclear hormone receptor
 EC50 11 - Homo sapiens
Estrogen receptor
Nuclear hormone receptor
 - - - Homo sapiens
Androgen receptor
Nuclear hormone receptor
 Ki 8.07 - Homo sapiens
Progesterone receptor
Nuclear hormone receptor
 ED50 9.876 - Homo sapiens
Corticosteroid-binding globulin
Secreted
 Ki 7.38 - Homo sapiens
Sex hormone-binding globulin
Secreted
 Kd 6.94 - Homo sapiens
Sterol O-acyltransferase 1
Enzyme
 IC50 4.77 - Homo sapiens
Fatty acid-binding protein, intestinal
Cytosolic other
 Ki 4.7 - Homo sapiens
Androgen receptor
Transcription factor
 IC50 5.81 - Rattus norvegicus
Fatty acid-binding protein, liver
Unclassified
 Ki 7.57 - Rattus norvegicus
Progesterone receptor
Transcription factor
 Ki 8.441 - Bos taurus
Sigma non-opioid intracellular receptor 1
Membrane receptor
 Kd 6.62 - Rattus norvegicus
Androgen receptor
Transcription factor
 IC50 7.43 - Mus musculus
Progesterone receptor
Transcription factor
 Ki 7.98 - Oryctolagus cuniculus
C-8 sterol isomerase
Enzyme
 Ki 5.35 - Saccharomyces cerevisiae (strain ATCC 204508 / S288c)
Sigma non-opioid intracellular receptor 1
Membrane other
 Ki 6.18 - Cavia porcellus
Steroid 5-alpha-reductase
Enzyme
 IC50 5.8 - Rattus norvegicus
Estrogen receptor
Transcription factor
 Kd 8.41 - Rattus norvegicus
Cation channel sperm-associated protein 1
Ion channel
 EC50 8.11 - Homo sapiens
Cation channel sperm-associated protein 2
Ion channel
 EC50 8.11 - Homo sapiens
Cation channel sperm-associated protein 3
Ion channel
 EC50 8.11 - Homo sapiens
Cation channel sperm-associated protein 4
Ion channel
 EC50 8.11 - Homo sapiens
Short transient receptor potential channel 5
Ion channel
 IC50 5.3 - Homo sapiens
P2X purinoceptor 3
Ion channel
 IC50 5.8 - Homo sapiens
SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Ovarian hyperstimulation syndrome 256 1098.394 10033266
Foetal exposure during pregnancy 450 686.448 10071404
Temperature regulation disorder 190 626.618 10061376
Food allergy 195 537.924 10016946
Exposure during pregnancy 449 508.4 10073513
Coeliac disease 191 500.941 10009839
Premature baby 276 459.115 10036590
Immunodeficiency 192 399.703 10061598
Maternal exposure during pregnancy 416 344.46 10071408
Bursitis 200 330.349 10006811
Premature labour 122 291.315 10036600
Rash erythematous 209 274.9 10037855
Abortion spontaneous 174 257.714 10000234
Premature delivery 142 238.165 10036595
Fluid retention 211 237.869 10016807
Foetal death 100 213.448 10055690
Upper respiratory tract infection 218 196.852 10046306
Death 27 185.256 10011906
Hyperhidrosis 261 175.416 10020642
Product adhesion issue 68 161.704 10069889
Atrial septal defect 88 154.611 10003664
Asthma 236 150.876 10003553
Gestational diabetes 67 147.303 10018209
Low birth weight baby 90 144.068 10067508
Vaginal haemorrhage 94 134.833 10046910
Headache 597 129.655 10019211
Maternal exposure before pregnancy 61 124.393 10071406
Small for dates baby 63 120.331 10041092
Meningioma 51 120.228 10027191
Erythema 271 117.753 10015150
Oligohydramnios 53 113.064 10030289
Pregnancy 97 110.661 10036556
Ventricular septal defect 61 108.418 10047298
Acute kidney injury 33 105.267 10069339
Toxicity to various agents 17 103.633 10070863
Pre-eclampsia 54 103.304 10036485
Drug hypersensitivity 338 102.283 10013700
Human herpesvirus 6 infection 48 98.564 10020431
Postmenopausal haemorrhage 33 93.949 10055870
Premature rupture of membranes 41 91.774 10036603
Autoimmune dermatitis 19 91.227 10075689
Hot flush 115 90.14 10060800
Foetal growth restriction 59 89.391 10070531
Pneumonia 91 86.604 10035664
Butterfly rash 31 85.828 10067982
Placenta accreta 19 84.857 10062936
Back pain 299 80.697 10003988
Congenital absence of vertebra 14 79.649 10010320
Constipation 281 72.845 10010774
Vulvovaginal discomfort 28 72.286 10047786

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR ligand-target interactions 9 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
Progesterone receptor
PGR
 Agonist 8.819999694824219 pEC50 9667968
Progesterone receptor
PGR
 Agonist 8.460000038146973 pKi 9464360
CatSper1
CATSPER1
 Full agonist 8.0 pEC50 21412339|21412338
CatSper2
CATSPER2
 Full agonist 8.109999656677246 pEC50 21412339|21412338
CatSper3
CATSPER3
 Full agonist 8.109999656677246 pEC50 21412339|21412338
CatSper4
CATSPER4
 Full agonist 8.109999656677246 pEC50 21412339|21412338
Glycine Receptor (All subtypes) Inhibition - 11522328
Mineralocorticoid receptor
NR3C2
 Antagonist 11.0 pIC50 8282004
TRPC5
TRPC5
 Inhibition 5.3 pIC50 21108630
SOURCE PharmGKB drug-gene phenotypes 4 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP2C9 (PA126) CYP2C9*1, CYP2C9*2, CYP2C9*3
CYP2C9 *1/*2 + *1/*3 + *2/*2 are not associated with exposure to progesterone in women as compared to CYP2C9 *1/*1.
Evidence: -; PMID 31482508
CYP2C19 (PA124) CYP2C19*1, CYP2C19*2, CYP2C19*17
CYP2C19 *1/*2 + *2/*17 are associated with increased exposure to progesterone in women as compared to CYP2C19 *1/*1.
Evidence: -; PMID 31482508
CYP2C19 (PA124) CYP2C19*1, CYP2C19*17
CYP2C19 *1/*17 + *17/*17 are not associated with exposure to progesterone in women as compared to CYP2C19 *1/*1.
Evidence: -; PMID 31482508
CYP2C19 CYP2C19*1, CYP2C19*2, CYP2C19*17
-
Evidence: 3; PMID 1
SOURCE RxNorm drug names 6 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
progesterone 8727 SU MTHSPL
PROGESTERONE 8727 SU MTHSPL
Progesterone 8727 SU MTHSPL
progesterone 8727 IN RXNORM
Crinone 153581 BN RXNORM
Prometrium 262140 BN RXNORM
SOURCE SIDER side-effect resource 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal bloating progesterone LLT C1291077
Abdominal discomfort progesterone LLT C0232487
Abdominal discomfort progesterone PT C0232487
Abdominal distension progesterone LLT C0000731
Abdominal distension progesterone PT C0000731
Abdominal distension progesterone PT C0000731
Abdominal pain progesterone LLT C0000737
Abdominal pain progesterone PT C0000737
Abnormal vision progesterone LLT C3665386
Abortion spontaneous progesterone LLT C0000786
Abortion spontaneous progesterone PT C0000786
Abscess progesterone LLT C0000833
Abscess progesterone PT C0000833
Accidental injury progesterone LLT C0151736
Acne progesterone LLT C0702166
Acne progesterone PT C0702166
Affect lability progesterone PT C0233472
Aggression progesterone LLT C0001807
Aggression progesterone PT C0001807
Alanine aminotransferase increased progesterone LLT C0151905
Alanine aminotransferase increased progesterone PT C0151905
Alopecia progesterone LLT C0002170
Alopecia progesterone PT C0002170
Amenorrhoea progesterone LLT C0002453
Amenorrhoea progesterone PT C0002453
Anaemia progesterone LLT C0002871
Anaemia progesterone PT C0002871
Anaphylactic shock progesterone LLT C0002792
Anaphylactic shock progesterone PT C0002792
Anaphylactic shock progesterone PT C0002792
Anaphylactoid reaction progesterone LLT C0340865
Anaphylactoid reaction progesterone PT C0340865
Angina pectoris progesterone LLT C0002962
Angina pectoris progesterone PT C0002962
Angioedema progesterone LLT C0002994
Angioedema progesterone PT C0002994
Angiopathy progesterone LLT C0042373
Angiopathy progesterone PT C0042373
Anorexia progesterone LLT C0003123
Anxiety progesterone LLT C0003467
Anxiety progesterone PT C0003467
Anxiety progesterone PT C0003467
Arthralgia progesterone LLT C0003862
Arthralgia progesterone PT C0003862
Arthritis progesterone LLT C0003864
Arthritis progesterone PT C0003864
Aspartate aminotransferase increased progesterone LLT C0151904
Aspartate aminotransferase increased progesterone PT C0151904
Assisted fertilisation progesterone PT C0521305
Asthenia progesterone LLT C0004093
Asthenia progesterone PT C0004093
Asthenia progesterone PT C0004093
Asthma progesterone LLT C0004096
Asthma progesterone PT C0004096
Asthma progesterone PT C0004096
Autonomic neuropathy progesterone PT C0259749
Back pain progesterone LLT C0004604
Back pain progesterone PT C0004604
Bladder pain progesterone PT C0232849
Bleeding breakthrough progesterone LLT C3495440
Blood and lymphatic system disorders progesterone - C0851353
Blood glucose increased progesterone LLT C0595877
Blood glucose increased progesterone PT C0595877
Blood pressure increased progesterone LLT C0497247
Blood pressure increased progesterone PT C0497247
Body temperature increased progesterone LLT C0015967
Body temperature increased progesterone PT C0015967
Bone pain progesterone LLT C0151825
Bone pain progesterone PT C0151825
Breast cancer progesterone PT C0006142
Breast discharge progesterone LLT C0149741
Breast discharge progesterone PT C0149741
Breast discomfort progesterone LLT C0877338
Breast discomfort progesterone PT C0877338
Breast disorder progesterone LLT C0006145
Breast disorder progesterone PT C0006145
Breast enlargement progesterone LLT C2225524
Breast enlargement progesterone PT C2225524
Breast pain progesterone LLT C0024902
Breast pain progesterone PT C0024902
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Progesterone used for in pharmaceutical contexts?

Progesterone (CAS 57-83-0) appears in DailyMed active-ingredient label rows, including Natural Progesterone.

What are the known adverse events for Progesterone?

Progesterone has 4,968 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Ovarian hyperstimulation syndrome, Foetal exposure during pregnancy, Temperature regulation disorder, Food allergy, Exposure during pregnancy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Progesterone also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Progesterone with EU status "prohibited".

What clinical phase is Progesterone in?

Progesterone is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Progesterone?

Progesterone has 36 bioactivity rows in this page query. Rendered target entries include Sodium/nucleoside cotransporter 1, Sigma non-opioid intracellular receptor 1, Multidrug resistance protein 1, Glucocorticoid receptor, Mineralocorticoid receptor.